SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001567619-22-009672
Filing Date
2022-05-06
Accepted
2022-05-06 16:12:29
Documents
2
Period of Report
2022-04-27

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 7807
2 poa_mcclure.htm EX-24 7469
  Complete submission text file 0001567619-22-009672.txt   16694
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Issuer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
McClure Matthew W. (Reporting) CIK: 0001927121 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39617 | Film No.: 22901176